Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(2.84)
# 1,650
Out of 4,842 analysts
131
Total ratings
27.87%
Success rate
2.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UBX Unity Biotechnology | Downgrades: Neutral | $4 → $2 | $0.68 | +193.69% | 9 | May 27, 2025 | |
| TARS Tarsus Pharmaceuticals | Assumes: Buy | $72 | $42.04 | +71.27% | 1 | May 27, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $10 | $2.22 | +350.45% | 13 | May 19, 2025 | |
| ZBIO Zenas BioPharma | Reiterates: Buy | $30 | $9.23 | +225.03% | 3 | May 16, 2025 | |
| ADVM Adverum Biotechnologies | Reiterates: Buy | $30 | $2.21 | +1,257.47% | 6 | May 15, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | $42 | $15.84 | +165.15% | 8 | May 13, 2025 | |
| SRZN Surrozen | Reiterates: Buy | $32 | $7.89 | +305.67% | 3 | May 12, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Buy | $38 | $28.35 | +34.04% | 5 | May 8, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 → $20 | $4.08 | +390.20% | 9 | May 2, 2025 | |
| IMUX Immunic | Reiterates: Buy | $10 | $0.91 | +998.66% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.77 | +1,452.59% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.01 | +696.02% | 3 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.85 | +8.40% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 | $3.50 | -14.29% | 4 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.41 | -41.35% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.67 | +19.76% | 16 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.18 | +139.23% | 4 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $4.39 | -54.44% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $3.47 | +937.46% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $231.79 | -87.92% | 1 | Aug 22, 2023 |
Unity Biotechnology
May 27, 2025
Downgrades: Neutral
Price Target: $4 → $2
Current: $0.68
Upside: +193.69%
Tarsus Pharmaceuticals
May 27, 2025
Assumes: Buy
Price Target: $72
Current: $42.04
Upside: +71.27%
Aldeyra Therapeutics
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $2.22
Upside: +350.45%
Zenas BioPharma
May 16, 2025
Reiterates: Buy
Price Target: $30
Current: $9.23
Upside: +225.03%
Adverum Biotechnologies
May 15, 2025
Reiterates: Buy
Price Target: $30
Current: $2.21
Upside: +1,257.47%
Mineralys Therapeutics
May 13, 2025
Reiterates: Buy
Price Target: $42
Current: $15.84
Upside: +165.15%
Surrozen
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $7.89
Upside: +305.67%
LENZ Therapeutics
May 8, 2025
Reiterates: Buy
Price Target: $38
Current: $28.35
Upside: +34.04%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $28 → $20
Current: $4.08
Upside: +390.20%
Immunic
May 1, 2025
Reiterates: Buy
Price Target: $10
Current: $0.91
Upside: +998.66%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $0.77
Upside: +1,452.59%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $1.01
Upside: +696.02%
Mar 31, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.85
Upside: +8.40%
Mar 31, 2025
Reiterates: Neutral
Price Target: $3
Current: $3.50
Upside: -14.29%
Mar 25, 2025
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.41
Upside: -41.35%
Mar 21, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.67
Upside: +19.76%
Mar 19, 2025
Maintains: Buy
Price Target: $7 → $10
Current: $4.18
Upside: +139.23%
Mar 14, 2025
Reiterates: Neutral
Price Target: $2
Current: $4.39
Upside: -54.44%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $3.47
Upside: +937.46%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $231.79
Upside: -87.92%